文献速递产科母胎医学

专家综述:产科静脉血栓栓塞症的预防

Expert review: prevention of obstetrical venous thromboembolism.
PubMed 文献 · Am J Obstet Gynecol · 2021-05-08

该专家综述聚焦产科静脉血栓栓塞症(VTE)预防,指出VTE占美国孕产妇死亡的9%至10%,且总体孕产妇死亡率自20世纪90年代末上升超40%。综述比较主要学会指南差异、讨论扩大肝素预防的正反论据,结论认为扩大肝素预防是温和干预,可能显著降低VTE死亡率。

要点

  • VTE占美国孕产妇死亡的9%至10%,总体孕产妇死亡率自20世纪90年代末上升超40%。
  • 英国2004年推荐更广泛肝素预防后死亡率显著下降,未发现出血所致死亡风险增加。
  • 专家结论:扩大肝素预防是温和干预,可能显著降低VTE死亡率。

核心结论

  • 基于现有最佳数据,扩大肝素预防是温和干预,可能显著降低VTE死亡率。

研究设计与样本

  • 专家综述,聚焦产前住院期间和剖宫产术后是否应常规使用肝素预防。

主要发现

  • VTE占美国孕产妇死亡的9%至10%,总体孕产妇死亡率自20世纪90年代末上升超40%。
  • 围手术期剖宫产机械血栓预防广泛采用与VTE事件风险降低相关,但不足以降低死亡率。
  • 英国2004年推荐更广泛肝素预防后死亡率显著下降,未发现出血所致死亡风险增加。

关键数值与推荐

  • 支持肝素预防的证据包括:英国证明安全有效;机械预防在围手术期外有重大局限;住院剖宫产和产前患者事件相对风险高。
  • 反对广泛肝素预防的专家引用安全性、有效性和成本担忧。

临床怎么用

  • 需权衡产前住院和剖宫产术后肝素预防的获益与安全性、有效性及成本。
  • 临床考虑包括肝素预防时椎管内麻醉的可及性。

局限性

  • 如何最佳改善预防高度争议,专家和指南存在分歧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venous thromboembolism represents a persistent proportionate cause of maternal mortality in the United States accounting for 9% to 10% of maternal deaths. Given that overall maternal mortality rose >40% since the late 1990s, it is likely that absolute venous thromboembolism mortality risk increased as well. This persistent risk may be secondary to increases in broad population-based risk factors for venous thromboembolism such as obesity and cesarean delivery. Widespread adoption of perioperative cesarean mechanical thromboprophylaxis is associated with reduced risk for venous thromboembolism events but has not been sufficient to reduce mortality. Experts agree that improved clinical care is required to reduce risk as it is unlikely that trends in venous thromboembolism risk factors will reverse course anytime soon. Experts further agree that improving prophylaxis and prevention may provide the largest benefit. However, how to best improve prophylaxis is highly controversial with both experts and guidelines in disagreement. In the United Kingdom, mortality risk decreased substantially following the 2004 recommendations for broader heparin prophylaxis without evidence of increased mortality risk from hemorrhage. A key clinical question in the United States is whether heparin prophylaxis should be expanded to patients hospitalized for cesarean delivery or an antepartum indication. Some experts, including us, support expanded heparin prophylaxis. Evidence supporting heparin prophylaxis includes (1) demonstration of safety and efficacy in the United Kingdom, (2) that mechanical prophylaxis-the primary alternative to heparin-has major limitations outside the immediate perioperative setting, and (3) that hospitalized cesarean and antepartum patients are at high relative risk of events. Experts against broader heparin prophylaxis cite concerns related to safety, efficacy, and cost. This expert review focused on whether heparin prophylaxis should be routinely used during antepartum hospitalizations and after cesarean delivery. First, we review the differences in major society guidelines. Second, we review arguments for and against broader heparin prophylaxis. Third, we discuss what future research may be most likely to further inform best practices. Fourth, we review practical clinical considerations with heparin prophylaxis, including access to neuraxial anesthesia. Given the best available data, we concluded that expanding heparin prophylaxis represents a modest intervention with the potential to meaningfully reduce venous thromboembolism mortality.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Friedman AM, D'Alton ME. Expert review: prevention of obstetrical venous thromboembolism. Am J Obstet Gynecol. 2021. PMID: 33974905. doi:10.1016/j.ajog.2021.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。